Persistence and costs with subcutaneous TNF-alpha inhibitors in immune-mediated rheumatic disease stratified by treatment line

Persistence and costs with subcutaneous TNF-alpha inhibitors in immune-mediated rheumatic disease stratified by treatment line

Axel Svedbom,1 Johan Dalén,1 Christopher M Black,2 Sumesh Kachroo2 1Mapi Group, Stockholm, Sweden; 2Merck & Co., Inc., Kenilworth, NJ, USA Objectives: The objectives of this study were to 1) describe and compare treatment persistence with first- and second-line subcutan...

Full description

Bibliographic Details
Main Authors: Svedbom A, Dalén J, Black CM, Kachroo S
Format: Article
Language:English
Published: Dove Medical Press 2017-01-01
Series:Patient Preference and Adherence
Subjects:
Persistence
Rheumatoid disease
Biologics
Rheumatoid arthritis
Psoriatic arthritis
Ankylosing spondylitis
Online Access:https://www.dovepress.com/persistence-and-costs-with-subcutaneous-tnf-alpha-inhibitors-in-immune-peer-reviewed-article-PPA

Internet

https://www.dovepress.com/persistence-and-costs-with-subcutaneous-tnf-alpha-inhibitors-in-immune-peer-reviewed-article-PPA

Similar Items